| DB ID | MyCo_3247 |
| Title | Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients |
| Year | 2014 |
| PMID | 25448310 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | HIV-AIDS |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The LSU HIV Translational Research Biorepository protocols were approved by the LSU Health Sciences Center Institutional Review Board and all subjects provided informed consent. The use of those samples for the current study was approved by the Tulane University Biomedical IRB in New Orleans, LA reference number 13-420174E. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Here analyzed serum and BAL lavage fluid from a cohort of 119 patients that did have HIV, a diagnosis of pneumonia and underwent bronchoscopy (FOB) for diagnosis of PCP. |
| Cohort No. | 119 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
